Dechra Pharmaceuticals Plc (DPH):企業の財務・戦略的SWOT分析

◆英語タイトル:Dechra Pharmaceuticals Plc (DPH) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH6739FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dechra Pharmaceuticals Plc (Dechra) is a manufacturer and distributor of veterinary pharmaceutical products. The company’s product portfolio includes vetoryl, felimazole, thyforon, malaseb, canaural, isaderm, cardisure, comfortan, soludox, methoxasol, cyclospray and octacillin, among others. Its products are used in the therapeutic areas of anaesthesia and analgesia; dermatology, pet diets and nutrition, endocrinology, cardiology, exotics and fluid therapy. Dechra manufactures human and veterinary pharmaceutical products for third party customers. The company exports its products to Denmark, Sweden, the US, the UK, Germany, Italy, France, Belgium, the Netherlands, Norway, Poland, Canada, Austria, and others. Dechra is headquartered in Northwich, England, the UK.

Dechra Pharmaceuticals Plc Key Recent Developments

Mar 31,2021: Dechra Pharmaceuticals: Announces Directorate change
Feb 22,2021: Dechra Pharmaceuticals : Half-yearly report six months to 31 December 2020
Feb 09,2021: Akston Biosciences Signs Licensing Agreement with Dechra Pharma for AKS-425c, a Once-a-Week Insulin Therapy for Cats
Jan 14,2021: Dechra Pharmaceuticals: Trading update and notice of half year results
Sep 07,2020: Dechra Pharmaceuticals: Preliminary Results Announcement

This comprehensive SWOT profile of Dechra Pharmaceuticals Plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Dechra Pharmaceuticals Plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Dechra Pharmaceuticals Plc – Key Information
Dechra Pharmaceuticals Plc – Overview
Dechra Pharmaceuticals Plc – Key Employees
Dechra Pharmaceuticals Plc – Key Employee Biographies
Dechra Pharmaceuticals Plc – Key Operational Heads
Dechra Pharmaceuticals Plc – Major Products and Services
Dechra Pharmaceuticals Plc – History
Dechra Pharmaceuticals Plc – Company Statement
Dechra Pharmaceuticals Plc – Locations And Subsidiaries
Dechra Pharmaceuticals Plc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Dechra Pharmaceuticals Plc – Business Description
Dechra Pharmaceuticals Plc – Corporate Strategy
Dechra Pharmaceuticals Plc – SWOT Analysis
SWOT Analysis – Overview
Dechra Pharmaceuticals Plc – Strengths
Dechra Pharmaceuticals Plc – Weaknesses
Dechra Pharmaceuticals Plc – Opportunities
Dechra Pharmaceuticals Plc – Threats
Dechra Pharmaceuticals Plc – Key Competitors

Section 3 – Company Financial Performance Charts

Dechra Pharmaceuticals Plc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Dechra Pharmaceuticals Plc, Key Information
Dechra Pharmaceuticals Plc, Key Ratios
Dechra Pharmaceuticals Plc, Share Data
Dechra Pharmaceuticals Plc, Major Products and Services
Dechra Pharmaceuticals Plc, History
Dechra Pharmaceuticals Plc, Key Employees
Dechra Pharmaceuticals Plc, Key Employee Biographies
Dechra Pharmaceuticals Plc, Key Operational Heads
Dechra Pharmaceuticals Plc, Other Locations
Dechra Pharmaceuticals Plc, Subsidiaries
Dechra Pharmaceuticals Plc, Key Competitors
Dechra Pharmaceuticals Plc, SWOT Analysis
Dechra Pharmaceuticals Plc, Ratios based on current share price
Dechra Pharmaceuticals Plc, Annual Ratios
Dechra Pharmaceuticals Plc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Dechra Pharmaceuticals Plc (DPH):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • StealthGas Inc (GASS):石油・ガス:M&Aディール及び事業提携情報
    Summary StealthGas Inc (StealthGas) is an oil and gas shipping company that offers seaborne and oil and gas transportation services. The company provides transportation of petroleum and petrochemical gas products in liquefied forms. It transports byproducts of crude oil and natural gas including but …
  • Haemonetics Corp (HAE):企業の製品パイプライン分析2018
    Summary Haemonetics Corp (Haemonetics) is a healthcare company that offers blood management technologies and software solutions. Its portfolio includes integrated devices, information management software, and consulting services for improving clinical outcomes. It also offers a comprehensive suite o …
  • National Jewish Health-製薬・医療分野:企業M&A・提携分析
    Summary National Jewish Health (NJH), formerly National Jewish Medical and Research Center is a healthcare center that offers treatment of pulmonary, cardiac, immune and related disorders. The center offers services in the areas of allergy, asthma, cardiology, clinical immunology, COPD, environmenta …
  • Toronto Hydro Corporation-エネルギー分野:企業M&A・提携分析
    Summary Toronto Hydro Corporation (Toronto Hydro) is a utility holding company, providing electricity distribution and street lighting services in Toronto through its subsidiaries: Toronto Hydro-Electric System Limited (LDC) and Toronto Hydro Energy Services Inc. (TH Energy). LDC conducts electricit …
  • Natcore Technology Inc (NXT):企業の財務・戦略的SWOT分析
    Summary Natcore Technology Inc (Natcore) is a solar research and development company that provides products for semiconductor and fiber optic applications. The company’s products include solar cell structures and black silicon cells. It uses liquid phase deposition technology for controlling deposit …
  • Nuformix Plc (NFX):製薬・医療:M&Aディール及び事業提携情報
    Summary Nuformix Plc (Nuformix), formerly Levrett plc, is a pharmaceutical company which develops cocrystal forms of approved small molecules. Its product candidates which are in clinical and pre-clinical development include NXP001, NXP002, and NXP003 for the treatment of oncology supportive care an …
  • Shinva Medical Instrument Co Ltd (600587):企業の財務・戦略的SWOT分析
    Shinva Medical Instrument Co Ltd (600587) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Global Petroleum Ltd (GBP):企業の財務・戦略的SWOT分析
    Summary Global Petroleum Ltd (Global Petroleum) is an oil and gas company that offers oil and gas exploration and development services. It operates through a portfolio of oil and gas projects in offshore Namibia and others. Its Namibian Project is into petroleum and gas exploration and Juan de Nova …
  • Harbin Electric Co Ltd (1133):企業の財務・戦略的SWOT分析
    Harbin Electric Co Ltd (1133) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • DxTerity Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary DxTerity Diagnostics Inc (DxTerity) is a medical device company that offers molecular diagnostic solutions. The company develops genomic tests for disease diagnosis. Its patient clinical research platform and dxcollect fingerstick collection kit are used for population scale genomic studies. …
  • Vectren Corp (VVC):企業の財務・戦略的SWOT分析
    Vectren Corp (VVC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • AES Gener SA (AESGENER):企業の財務・戦略的SWOT分析
    AES Gener SA (AESGENER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Fujifilm SonoSite Inc:医療機器:M&Aディール及び事業提携情報
    Summary Fujifilm SonoSite Inc (Fujifilm SonoSite), a subsidiary of Fujifilm Holdings Corp, is a medical device company. It designs and develops ultrasound systems for use in a variety of medical specialties including anesthesiology, cardiology, critical care, endocrinology, orthopedic surgery, radio …
  • Cardinal Health, Inc.:企業の戦略・SWOT・財務情報
    Cardinal Health, Inc. - Strategy, SWOT and Corporate Finance Report Summary Cardinal Health, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • HCR ManorCare, Inc.:企業の戦略・SWOT・財務情報
    HCR ManorCare, Inc. - Strategy, SWOT and Corporate Finance Report Summary HCR ManorCare, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Osmotica Pharmaceutical Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Osmotica Pharmaceutical Corp (Osmotica) is a pharmaceutical company that specializes in drug delivery technologies and neurology based therapies. The company provides product portfolio such as nifedipine, oxybutynin, venlafaxine and desvenlafaxine, among others. It offers capabilities such a …
  • Moneysupermarket.com Group PLC (MONY):企業の財務・戦略的SWOT分析
    Moneysupermarket.com Group PLC (MONY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Rubicon Genomics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Rubicon Genomics Inc (Rubicon Genomics), a subsidiary of the Takara Bio Group is a provider of pre-analytical amplification technologies. The company offers various types of kits for whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing, copy number variation (CNV) …
  • XBiotech Inc (XBIT):企業の財務・戦略的SWOT分析
    Summary XBiotech Inc (XBiotech) is a biopharmaceutical company that discovers, develops and commercialize therapeutic antibodies based proprietary technology. The company offers monoclonal antibodies treatment for various diseases. It’s lead product Xilonix, a therapeutic antibody being developed fo …
  • Jazeera Airways Company KSC:企業の戦略・SWOT・財務情報
    Jazeera Airways Company KSC - Strategy, SWOT and Corporate Finance Report Summary Jazeera Airways Company KSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆